vs
亚什兰（ASH）与MADRIGAL PHARMACEUTICALS, INC.（MDGL）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是MADRIGAL PHARMACEUTICALS, INC.的1.2倍（$386.0M vs $321.1M），亚什兰净利率更高（-3.1% vs -18.2%，领先15.1%），MADRIGAL PHARMACEUTICALS, INC.同比增速更快（210.8% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $-133.8M）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
本公司是一家美国生物制药企业，成立于2002年，专注于研发新型合成胆汁酸类似物，可用于治疗原发性胆汁性胆管炎、非酒精性脂肪肝、肝硬化等慢性肝病，以及胆汁酸性腹泻等肠道疾病。
ASH vs MDGL — 直观对比
营收规模更大
ASH
是对方的1.2倍
$321.1M
营收增速更快
MDGL
高出215.5%
-4.7%
净利率更高
ASH
高出15.1%
-18.2%
自由现金流更多
ASH
多$244.8M
$-133.8M
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $321.1M |
| 净利润 | $-12.0M | $-58.6M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | -18.6% |
| 净利率 | -3.1% | -18.2% |
| 营收同比 | -4.7% | 210.8% |
| 净利润同比 | 92.7% | 1.4% |
| 每股收益（稀释后） | $-0.26 | $-2.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHMDGL
| Q4 25 | $386.0M | $321.1M | ||
| Q3 25 | $477.0M | $287.3M | ||
| Q2 25 | $463.0M | $212.8M | ||
| Q1 25 | $479.0M | $137.3M | ||
| Q4 24 | $405.0M | $103.3M | ||
| Q3 24 | $521.0M | $62.2M | ||
| Q2 24 | $544.0M | — | ||
| Q1 24 | $575.0M | $0 |
净利润ASHMDGL
| Q4 25 | $-12.0M | $-58.6M | ||
| Q3 25 | $31.0M | $-114.2M | ||
| Q2 25 | $-742.0M | $-42.3M | ||
| Q1 25 | $31.0M | $-73.2M | ||
| Q4 24 | $-165.0M | $-59.4M | ||
| Q3 24 | $17.0M | $-107.0M | ||
| Q2 24 | $6.0M | — | ||
| Q1 24 | $120.0M | $-147.5M |
毛利率ASHMDGL
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 30.7% | 96.7% | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | — | ||
| Q2 24 | 34.2% | — | ||
| Q1 24 | 28.0% | — |
营业利润率ASHMDGL
| Q4 25 | -1.6% | -18.6% | ||
| Q3 25 | 12.8% | -39.7% | ||
| Q2 25 | -152.9% | -22.2% | ||
| Q1 25 | 10.6% | -57.8% | ||
| Q4 24 | -44.2% | -64.8% | ||
| Q3 24 | 6.1% | -187.1% | ||
| Q2 24 | -11.2% | — | ||
| Q1 24 | 3.7% | — |
净利率ASHMDGL
| Q4 25 | -3.1% | -18.2% | ||
| Q3 25 | 6.5% | -39.8% | ||
| Q2 25 | -160.3% | -19.9% | ||
| Q1 25 | 6.5% | -53.4% | ||
| Q4 24 | -40.7% | -57.5% | ||
| Q3 24 | 3.3% | -172.0% | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 20.9% | — |
每股收益（稀释后）ASHMDGL
| Q4 25 | $-0.26 | $-2.55 | ||
| Q3 25 | $0.83 | $-5.08 | ||
| Q2 25 | $-16.21 | $-1.90 | ||
| Q1 25 | $0.65 | $-3.32 | ||
| Q4 24 | $-3.50 | $-2.50 | ||
| Q3 24 | $0.34 | $-4.92 | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $2.39 | $-7.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $198.7M |
| 总债务越低越好 | $1.4B | $339.9M |
| 股东权益账面价值 | $1.9B | $602.7M |
| 总资产 | $4.5B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资ASHMDGL
| Q4 25 | $304.0M | $198.7M | ||
| Q3 25 | $215.0M | $295.7M | ||
| Q2 25 | $207.0M | $186.2M | ||
| Q1 25 | $168.0M | $183.6M | ||
| Q4 24 | $219.0M | $100.0M | ||
| Q3 24 | $300.0M | $232.7M | ||
| Q2 24 | $399.0M | — | ||
| Q1 24 | $439.0M | $622.5M |
总债务ASHMDGL
| Q4 25 | $1.4B | $339.9M | ||
| Q3 25 | $1.4B | $339.8M | ||
| Q2 25 | $1.4B | $118.4M | ||
| Q1 25 | $1.3B | $118.0M | ||
| Q4 24 | $1.3B | $117.6M | ||
| Q3 24 | $1.3B | $117.1M | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | $116.1M |
股东权益ASHMDGL
| Q4 25 | $1.9B | $602.7M | ||
| Q3 25 | $1.9B | $625.7M | ||
| Q2 25 | $1.9B | $696.0M | ||
| Q1 25 | $2.6B | $710.6M | ||
| Q4 24 | $2.6B | $754.4M | ||
| Q3 24 | $2.9B | $777.2M | ||
| Q2 24 | $3.0B | — | ||
| Q1 24 | $3.1B | $850.8M |
总资产ASHMDGL
| Q4 25 | $4.5B | $1.3B | ||
| Q3 25 | $4.6B | $1.4B | ||
| Q2 25 | $4.6B | $1.0B | ||
| Q1 25 | $5.2B | $996.6M | ||
| Q4 24 | $5.2B | $1.0B | ||
| Q3 24 | $5.6B | $1.1B | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.9B | $1.1B |
负债/权益比ASHMDGL
| Q4 25 | 0.74× | 0.56× | ||
| Q3 25 | 0.73× | 0.54× | ||
| Q2 25 | 0.73× | 0.17× | ||
| Q1 25 | 0.52× | 0.17× | ||
| Q4 24 | 0.51× | 0.16× | ||
| Q3 24 | 0.47× | 0.15× | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $-133.5M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $-133.8M |
| 自由现金流率自由现金流/营收 | 28.8% | -41.7% |
| 资本支出强度资本支出/营收 | 3.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHMDGL
| Q4 25 | $125.0M | $-133.5M | ||
| Q3 25 | $40.0M | $79.8M | ||
| Q2 25 | $115.0M | $-47.1M | ||
| Q1 25 | $9.0M | $-88.9M | ||
| Q4 24 | $-30.0M | $-104.5M | ||
| Q3 24 | $80.0M | $-67.0M | ||
| Q2 24 | $127.0M | — | ||
| Q1 24 | $54.0M | $-149.2M |
自由现金流ASHMDGL
| Q4 25 | $111.0M | $-133.8M | ||
| Q3 25 | $6.0M | $79.0M | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $-12.0M | — | ||
| Q4 24 | $-53.0M | $-104.7M | ||
| Q3 24 | $42.0M | $-67.8M | ||
| Q2 24 | $98.0M | — | ||
| Q1 24 | $20.0M | $-149.5M |
自由现金流率ASHMDGL
| Q4 25 | 28.8% | -41.7% | ||
| Q3 25 | 1.3% | 27.5% | ||
| Q2 25 | 20.5% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | -13.1% | -101.3% | ||
| Q3 24 | 8.1% | -109.0% | ||
| Q2 24 | 18.0% | — | ||
| Q1 24 | 3.5% | — |
资本支出强度ASHMDGL
| Q4 25 | 3.6% | 0.1% | ||
| Q3 25 | 7.1% | 0.3% | ||
| Q2 25 | 4.3% | 0.0% | ||
| Q1 25 | 4.4% | 0.0% | ||
| Q4 24 | 5.7% | 0.2% | ||
| Q3 24 | 7.3% | 1.3% | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 5.9% | — |
现金转化率ASHMDGL
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
